Jim Simons Biotechnology

Renaissance Technologies LLC

$70.6 Billion
Q3 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
GOSS Gossamer Bio, Inc.	$255M	$7.84 Million 0.01% of portfolio	2,980,188	Q3 2025 Added 9.07%
KURA Kura Oncology, Inc.	$749M	$7.66 Million 0.01% of portfolio	865,310	Q3 2025 Reduced 18.14%
KOD Kodiak Sciences Inc.	$1.02B	$7.55 Million 0.01% of portfolio	461,300	Q3 2025 Reduced 39.63%
ETNB 89bio, Inc.	$690M	$7.49 Million 0.01% of portfolio	510,500	Q3 2025 Reduced 0.56%
ETON Eton Pharmaceuticals, Inc.	$428M	$7.09 Million 0.01% of portfolio	324,621	Q3 2025 Reduced 20.02%
SANA Sana Biotechnology, Inc.	$759M	$7.07 Million 0.01% of portfolio	1,992,500	Q3 2025 Added 878.1%
SGMO Sangamo Therapeutics, Inc	$68.9M	$6.82 Million 0.01% of portfolio	10,182,463	Q3 2025 Added 48.88%
VIR Vir Biotechnology, Inc.	$747M	$6.66 Million 0.01% of portfolio	1,167,100	Q3 2025 Added 9.64%
DAWN Day One Biopharmaceuticals, Inc.	$646M	$6.38 Million 0.01% of portfolio	905,476	Q3 2025 Reduced 9.5%
ENTA Enanta Pharmaceuticals Inc	$250M	$5.74 Million 0.01% of portfolio	479,600	Q3 2025 Added 2.15%
ARVN Arvinas, Inc.	$562M	$5.71 Million 0.01% of portfolio	669,655	Q3 2025 Reduced 44.86%
AKRO Akero Therapeutics, Inc.	$2.52B	$5.61 Million 0.01% of portfolio	118,100	Q3 2025 Added 321.79%
URGN Uro Gen Pharma Ltd.	$553M	$5.37 Million 0.01% of portfolio	275,100	Q3 2025 Added 620.16%
RLAY Relay Therapeutics, Inc.	$756M	$5.34 Million 0.01% of portfolio	1,023,110	Q3 2025 Reduced 32.16%
IMCR Immunocore Holdings PLC	$1.58B	$5.19 Million 0.01% of portfolio	142,770	Q3 2025 Reduced 35.7%
TERN Terns Pharmaceuticals, Inc.	$846M	$5.14 Million 0.01% of portfolio	676,834	Q3 2025 Reduced 26.63%
CLDX Celldex Therapeutics, Inc.	$1.2B	$5.03 Million 0.01% of portfolio	194,588	Q3 2025 Added 7.28%
MNKD Mannkind Corp	$1.3B	$4.57 Million 0.01% of portfolio	850,797	Q3 2025 Reduced 39.79%
EDIT Editas Medicine, Inc.	$179M	$4.43 Million 0.01% of portfolio	1,277,400	Q3 2025 Added 43.79%
CDXC Chroma Dex Corp.	$420M	$4.38 Million 0.01% of portfolio	713,000	Q3 2025 Added 45.63%
DYN Dyne Therapeutics, Inc.	$975M	$4.37 Million 0.01% of portfolio	345,500	Q3 2025 New
ADPT Adaptive Biotechnologies Corp	$2.01B	$4.18 Million 0.01% of portfolio	279,700	Q3 2025 Added 460.52%
BCYC Bicycle Therapeutics PLC	$192M	$4.01 Million 0.01% of portfolio	518,700	Q3 2025 Added 62.91%
CNTA Centessa Pharmaceuticals PLC	$2.6B	$3.99 Million 0.01% of portfolio	164,600	Q3 2025 Reduced 57.24%
HRTX Heron Therapeutics, Inc.	$131M	$3.65 Million 0.01% of portfolio	2,854,999	Q3 2025 Added 6.16%
PRTA Prothena Corp Public LTD CO	$466M	$3.62 Million 0.01% of portfolio	371,300	Q3 2025 Added 311.64%
ALLO Allogene Therapeutics, Inc.	$177M	$3.59 Million 0.01% of portfolio	2,893,812	Q3 2025 Added 73.28%
AVIR Atea Pharmaceuticals, Inc.	$246M	$3.56 Million 0.01% of portfolio	1,227,900	Q3 2025 Reduced 0.5%
ZNTL Zentalis Pharmaceuticals, Inc.	$75.8M	$3.51 Million 0.0% of portfolio	2,325,355	Q3 2025 Added 52.03%
TRDA Entrada Therapeutics, Inc.	$274M	$3.45 Million 0.0% of portfolio	594,300	Q3 2025 Added 56.6%
COGT Cogent Biosciences, Inc.	$2.21B	$3.35 Million 0.0% of portfolio	232,968	Q3 2025 New
LCTX Lineage Cell Therapeutics, Inc.	$323M	$3.3 Million 0.0% of portfolio	1,905,633	Q3 2025 Reduced 3.38%
GERN Geron Corp	$423M	$3.24 Million 0.0% of portfolio	2,364,280	Q3 2025 Reduced 52.71%
CGEM Cullinan Oncology, Inc.	$390M	$3.14 Million 0.0% of portfolio	529,408	Q3 2025 Added 58.26%
CABA Cabaletta Bio, Inc.	$67M	$3.12 Million 0.0% of portfolio	1,339,423	Q3 2025 Added 962.19%
RGNX Regenxbio Inc.	$498M	$2.99 Million 0.0% of portfolio	309,486	Q3 2025 Reduced 57.9%
RCUS Arcus Biosciences, Inc.	$1.45B	$2.98 Million 0.0% of portfolio	219,300	Q3 2025 Reduced 40.42%
PLX Protalix Bio Therapeutics, Inc.	$92.5M	$2.93 Million 0.0% of portfolio	1,315,400	Q3 2025 Reduced 18.55%
GLUE Monte Rosa Therapeutics, Inc.	$671M	$2.93 Million 0.0% of portfolio	395,733	Q3 2025 Reduced 35.66%
PCVX Vaxcyte, Inc.	$2.89B	$2.9 Million 0.0% of portfolio	80,477	Q3 2025 Reduced 70.09%
MGNX Macrogenics Inc	$94.6M	$2.89 Million 0.0% of portfolio	1,701,223	Q3 2025 Added 28.25%
ATXS Astria Therapeutics, Inc.	$191M	$2.85 Million 0.0% of portfolio	395,261	Q3 2025 Added 36.4%
ALEC Alector, Inc.	$102M	$2.81 Million 0.0% of portfolio	949,150	Q3 2025 Reduced 24.36%
ABEO Abeona Therapeutics Inc.	$26.5M	$2.78 Million 0.0% of portfolio	526,437	Q3 2025 Added 75.52%
LRMR Larimar Therapeutics, Inc.	$146M	$2.77 Million 0.0% of portfolio	858,642	Q3 2025 Added 52.85%
SPRO Spero Therapeutics, Inc.	$84.5M	$2.73 Million 0.0% of portfolio	1,452,765	Q3 2025 Added 74.58%
FDMT 4 D Molecular Therapeutics, Inc.	$351M	$2.64 Million 0.0% of portfolio	313,186	Q3 2025 Added 168.71%
TRVI Trevi Therapeutics, Inc.	$661M	$2.62 Million 0.0% of portfolio	293,300	Q3 2025 Reduced 40.06%
OVID Ovid Therapeutics Inc.	$92.2M	$2.58 Million 0.0% of portfolio	2,018,024	Q3 2025 Reduced 3.69%
TNYA Tenaya Therapeutics, Inc.	$56.3M	$2.57 Million 0.0% of portfolio	1,678,202	Q3 2025 Reduced 8.99%

Shares Options

Jim Simons

Jim Simons is the founder and chairman of Renaissance Technologies, a successful investment firm that uses quantitative approaches to investing. Simons is known for his expertise in mathematical modeling and has a reputation for being a skilled and successful investor. He has generated strong returns for his clients over the long term.

Track Jim Simons's portfolio

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account